Cefiderocol Sulfate Tosylate

China [CN]

1. Core Uses

Approved Indications (all for intravenous administration):

Complicated urinary tract infections (cUTI) (including pyelonephritis, adults)

Hospital-acquired pneumonia (HAP) / Ventilator-associated pneumonia (VAP) (adults)

Bloodstream infections (BSI) (caused by CRE/XDR Gram-negative bacteria)

Mechanism: Siderophore-mediated ferric iron chelation, actively penetrating the outer membrane via bacterial iron transport proteins (e.g., TonB-dependent system), bypassing permeability barriers; stable against almost all β-lactamases, directly binding to PBPs to inhibit cell wall synthesis, achieving anti-CRE/XDR activity.

2. Key Clinical Information

Dosage Form: Sterile powder for injection (1g, calculated as cefiderocol)

Dosage and Administration: Adults 1g every 8 hours, intravenous infusion over 1 hour; dose reduction required for patients with renal impairment (CrCl < 60 mL/min)

Core Advantages:

Siderophore-mediated active transport: The only cephalosporin that can actively penetrate the outer membrane of Gram-negative bacteria, overcoming resistance barriers

Highly enzyme stable: Stable against serine/metallobeta-lactamases such as KPC, NDM, VIM, and OXA

Broad-spectrum coverage: Potent activity against CRE, XDR Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia

Suitable for severe infections: Used for carbapenem-resistant bacterial infections, filling a clinical gap and reducing mortality